profit from every SEK 100 of sales.
SEK 0SEK 100
Xvivo Perfusion
SEK 206.00+1.58% today
+11.8% in 1 year
1-year low SEK 174.801-year high SEK 309.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay SEK 257.87 for every SEK 1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Xvivo Perfusion sold, what it kept, and what it did with the cash.
Sales went from SEK 415 million in 2022 to SEK 812 million in 2025, with SEK 25.2 million of profit last year.
SalesProfit
Xvivo Perfusion vs. similar companies
Xvivo Perfusion grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from SEK 100 of sales | Sales growth a year | Price per SEK 1 of profit |
|---|---|---|---|
| Xvivo Perfusion | 257.9× · Very expensive | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads Xvivo Perfusion's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 415 | 598 | 822 | 812 | |
| 297 | 445 | 616 | 599 | |
| 4 | 5 | 89 | 92 | |
| 65 | 172 | 289 | 112 | |
| 18 | 92 | 172 | 25 | |
| 0.62 | 3.07 | 5.44 | 0.80 | |
| 71.5% | 74.5% | 75.0% | 73.8% | |
| 1.1% | 0.9% | 10.9% | 11.3% | |
| 4.4% | 15.4% | 20.9% | 3.1% |
Balance sheet
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,733 | 2,196 | 2,403 | 2,374 |
| Cash | 246 | 546 | 416 | 292 |
| Total debt | 10 | 31 | 34 | 125 |
| Total liabilities | 303 | 251 | 246 | 261 |
| 1,430 | 1,945 | 2,157 | 2,113 | |
| 30 | 30 | 32 | 32 | |
| 1.3% | 3.8% | 7.3% | 1.5% | |
| 1.3% | 4.7% | 8.0% | 1.2% |
Cash flow
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 28 | 46 | 111 | 101 | |
| 131 | 144 | 193 | 253 | |
| -103 | -98 | -82 | -152 | |
| Dividends paid | – | – | – | – |
| 0 | – | – | – | |
| 0 | 2 | 7 | 14 |
Valuation
- 257.9×
- –
- 29.08
- 4.0×
- 8.0×
- –
- 56.3×
- -2.3%
- 0.4%
- –
Profitability
- 73.8%
- 11.3%
- 3.1%
- –
- 1.5%
- 3.5%
- –
- –
- –
- –
Growth
- +25.1%
- +8.9%
- –
- –
- +2.2%
Financial health
- -1.5×
- 0.06
- –
- 12.1×
- 5.77
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 40%of 946
Top 45%of 872
Bottom 1%of 563
Top 23%of 868
Bottom 29%of 986
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
60Pass
Philip Fisher
50No pass
Peter Lynch
57No pass
Joel Greenblatt
1No pass
Charlie Munger
41No pass
Terry Smith
41No pass
Questions about Xvivo Perfusion
Is Xvivo Perfusion a good stock to buy?
A business with weak numbers, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Xvivo Perfusion AI analysis
What does Xvivo Perfusion do?
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. It is in Medical Devices, based in Mölndal, Sweden, with 199 employees.
Is Xvivo Perfusion stock halal?
Yes. Xvivo Perfusion passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Xvivo Perfusion stock done over the past year?
Up 11.8% over the past twelve months, to SEK 206.00. It traded between SEK 174.80 and SEK 309.00 and is 33.3% below its high.
Who are Xvivo Perfusion's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Xvivo Perfusion's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.